MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital Arnau de Vilanova](/img/noimage_org.png)
Hospital Arnau de Vilanova
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Arnau de Vilanova (38)
2024
-
Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis
Critical Reviews in Oncology/Hematology, Vol. 201
2023
-
MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions
International journal of molecular sciences, Vol. 24, Núm. 18
2021
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
2020
-
Breakthrough cancer pain: review and calls to action to improve its management
Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1216-1226
-
Predictors of indwelling pleural catheter removal and infection: A single-center experience with 336 procedures
Journal of Bronchology and Interventional Pulmonology, Vol. 27, Núm. 2, pp. 86-94
-
Prognostic factors involved in the epithelial– mesenchymal transition process in colorectal cancer have a preponderant role in oxidative stress: A systematic review and meta-analysis
Cancers, Vol. 12, Núm. 11, pp. 1-28
2019
-
Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions
Respirology, Vol. 24, Núm. 8, pp. 799-804
-
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Cancer Chemotherapy and Pharmacology, Vol. 83, Núm. 6, pp. 1175-1181
2018
-
Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer
Cancer Treatment and Research Communications, Vol. 16, pp. 13-17
2017
-
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Tumor Biology, Vol. 39, Núm. 6
-
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786
-
Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion
Lung, Vol. 195, Núm. 6, pp. 775-779
2016
-
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Targeted Oncology, Vol. 11, Núm. 3, pp. 293-308
-
Identifying thoracic malignancies through pleural fluid biomarkers: A predictive multivariate model
Medicine (United States), Vol. 95, Núm. 10
2015
-
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: A meta-analysis
Chest, Vol. 147, Núm. 2, pp. 502-512
-
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728
-
Clinical features and survival of lung cancer patients with pleural effusions
Respirology, Vol. 20, Núm. 4, pp. 654-659
-
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer
PLoS ONE, Vol. 10, Núm. 1
-
TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions
Respirology, Vol. 20, Núm. 5, pp. 831-833